Remarkably, only the combination of T-VEC and trabectedin significantly increased the proportion of T cells directed at the known tumor-associated endogenous retrovirus antigen, the envelope glycoprotein gp70, compared to the individual T-VEC or trabectedin treatments. Here, ERVW-1 is linked to neoplasm.